urocortin III Activators
Urocortin III is a member of the corticotropin-releasing factor (CRF) family, which plays a significant role in regulating stress responses, cardiovascular function, and metabolic processes. As a peptide, urocortin III predominantly exerts its effects through interaction with specific G-protein coupled receptors (GPCRs), namely the CRF receptors, with a high affinity for CRF2 receptors. The activation of these receptors by urocortin III can initiate a cascade of intracellular signaling events, leading to various physiological responses. These responses include modulation of stress-related behaviors, influence on cardiovascular dynamics, and involvement in energy balance. The mechanisms through which urocortin III is activated and functions are complex, involving multiple signaling pathways that can be influenced by cellular context, receptor distribution, and the presence of various intracellular mediators.
The general mechanisms of activation for urocortin III involve its binding to CRF receptors, which triggers G-protein signaling cascades, leading to the activation of adenylate cyclase and the increase of cyclic AMP (cAMP) levels. This elevation in cAMP is pivotal as it serves as a second messenger in cells, activating protein kinase A (PKA) and other downstream effectors that modulate gene expression, cellular metabolism, and cytoskeletal rearrangements. Additionally, urocortin III signaling can interact with other pathways, such as those mediated by calcium ions and protein kinase C (PKC), further diversifying its physiological roles. The activation of these signaling cascades by urocortin III contributes to its ability to regulate stress responses, cardiovascular function, and metabolic processes, highlighting the importance of understanding the specific biochemical and cellular contexts in which urocortin III operates. The specificity of chemical activators, as detailed in the table, underscores the complex interplay between various signaling molecules and pathways in modulating the activity of urocortin III, illustrating the intricacies of cellular signaling networks and the potential for targeted modulation of specific pathways to influence the functional outcomes associated with urocortin III activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly activates adenylate cyclase, leading to an increase in cyclic AMP (cAMP) levels. Elevated cAMP acts as a second messenger, activating protein kinase A (PKA). PKA activation can enhance the signaling pathways that involve urocortin III, leading to its functional activation by promoting cellular responses that are mediated by urocortin III. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a beta-adrenergic agonist, indirectly activates urocortin III through the stimulation of beta-adrenergic receptors, leading to the activation of adenylate cyclase and a subsequent rise in cAMP levels. This cascade activates PKA, which is involved in the signaling pathways that promote urocortin III-mediated effects in the heart and other tissues. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits phosphodiesterase-4 (PDE4), leading to an increase in cAMP levels within cells. This accumulation of cAMP activates PKA, which then engages in the phosphorylation of proteins that are part of the signaling pathways involving urocortin III, thereby promoting its activation and enhancing its cellular effects. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX acts as a non-selective inhibitor of phosphodiesterases, leading to increased levels of cAMP and cGMP. The rise in cAMP levels activates PKA, which then phosphorylates target proteins within the urocortin III signaling pathway, facilitating urocortin III activation and its physiological actions. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin acts as a protein synthesis inhibitor, but interestingly, it can also activate stress-activated protein kinases (SAPKs), which are part of the signaling pathways that urocortin III may modulate. Activation of these kinases can lead to cellular stress responses that indirectly enhance the activity of urocortin III. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which plays a critical role in numerous signaling pathways, including those that involve urocortin III. Activation of PKC can lead to downstream effects that promote the functional activation of urocortin III, including alterations in cellular calcium signaling and other mechanisms. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR activates AMP-activated protein kinase (AMPK), a key regulator of cellular energy homeostasis. Through the activation of AMPK, AICAR can influence signaling pathways that urocortin III is part of, leading to its activation by promoting cellular responses to metabolic stress. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterase 5 (PDE5), causing an increase in cGMP levels, which can indirectly influence cAMP pathways. This can lead to the activation of PKA, indirectly supporting the activation of urocortin III by modulating signaling pathways that involve cAMP and cGMP. | ||||||
L-NG-Nitroarginine Methyl Ester (L-NAME) | 51298-62-5 | sc-200333 sc-200333A sc-200333B | 1 g 5 g 25 g | $48.00 $107.00 $328.00 | 45 | |
L-NAME inhibits nitric oxide synthase, reducing nitric oxide (NO) levels. Decreased NO can modulate cGMP-dependent pathways, indirectly affecting cAMP levels and PKA activity. This modulation can support the activation of urocortin III by influencing signaling pathways that are responsive to changes in cellular stress and metabolic conditions. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin modulates various signaling pathways, including those involving NF-κB and AMPK, which can influence the cellular environment in a way that supports the activation of urocortin III. By modulating these pathways, curcumin can promote cellular conditions favorable to urocortin III activation. | ||||||